Licensed medicine
A regulator has licensed it for at least one use, in at least one country. That says nothing about uses outside the license.
This page is a stub
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
How strong is the evidence
How far it has climbed
Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.
- Licensed medicine: Abaloparatide
A regulator has reviewed the trials and licensed it for a named use.
- Phase 3
Large randomized trials, often thousands of people, against placebo or a standard treatment.
- Phase 2
Mid-sized trials that measure dose against effect in people with the condition.
- Phase 1 and early human studies
First studies in people: safety, and how the body handles it.
- Cells and animals
Laboratory and animal work. An animal result is not a result in people.
- 411
- papers on PubMed
- 268
- of them in people
- 32
- randomized trials
- 167
- reviews
A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16
Handling and reconstitution
From powder to a measured sample
The same four steps for any lyophilized vial. Laboratory handling, not use in a person.
1. Read the vial
The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.
2. Add the diluent
A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.
3. Work out the strength
Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.
4. Measure the sample
Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.
The calculator below does the arithmetic and shows its working.
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on Abaloparatide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Abaloparatide; no amount here is a recommendation.
Abaloparatide: on PubMed
What PubMed held for Abaloparatide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 411
- papers
- 268
- in humans
- 37
- clinical trials
- 32
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians
ReviewAyers C, Kansagara D, Lazur B, et al. Annals of internal medicine, 2023. PMID 36592455
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials
ReviewHändel MN, Cardoso I, von Bülow C, et al. BMJ (Clinical research ed.), 2023. PMID 37130601
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial
Randomized trialMiller PD, Hattersley G, Riis BJ, et al. JAMA, 2016. PMID 27533157
- ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
Randomized trialBone HG, Cosman F, Miller PD, et al. The Journal of clinical endocrinology and metabolism, 2018. PMID 29800372
- Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis
StudyBarrionuevo P, Kapoor E, Asi N, et al. The Journal of clinical endocrinology and metabolism, 2019. PMID 30907957
- The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis
Meta-analysisXu F, Wang Y, Zhu X Clinical therapeutics, 2024. PMID 38307725
- Abaloparatide
StudyAkel M, Patel P, Parmar M , 2024. PMID 36512663
- Osteoporosis: A Review
ReviewMorin SN, Leslie WD, Schousboe JT JAMA, 2025. PMID 40587168
Search used: ("Abaloparatide"[tiab]). Run it on PubMed
Research links
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for Abaloparatide on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.